Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shareholders have been strung out to dry.
IPIX is dead.
From the CEO - The Company historically devoted most of its efforts and resources on drug development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.
Update from the CEO -
Management’s Plan of Operation -
The Company historically devoted most of its efforts and resources on drug development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.
IPIX is dead.
Will investors learn in this 10Q that the CEO wrote Brilacidin off just as he recently did with Kevetrin? Wouldn’t surprise me.
Birds of a feather flock together.
No one can come up with anything bad to say about the co-founders of BT BeaMed Technologies
”what an unmitigated disaster”
Our problem due to financial concerns is when???
LOL. The CEO mentioned Regeneron the day IPIX died. 120,000,000 shares dumped by longs who simply had enough of this regurgitated bullshit.
The price has dropped another 80% since that day.
http://www.ipharminc.com/press-release/2021/11/11/innovation-pharmaceuticals-announces-topline-results-from-phase-2-clinical-trial-of-brilacidin-for-covid-19
“The early bird catches the worm. We better watch out or others will be the first to market a Peptide based antiinfective.”
Our bird is poolside stashing paychecks. In the CEO’s own words from Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Another dead end.
In the context of retirement it is. Especially for someone that’s been pulling in $10-$15k/month for years on end.
Early 60’s is not old…..I hope!
Sounds dreamy…. The CEO is an old fart who’s got what’s left of his sight on retirement IMO.
The CEO told us where we are headed in the last filing….
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170721710
LMAO. I’m sure he could afford the taxes too, but chose to surrender his shares. That’s the point.
Buy the shares back w/ what money? He’s only pulling in between $10-$15,000 every week in compensation from IPIX.
Leo can buy these shares back after January 30th.....this means there will be no news until sometime in February.....JMO!!!!!!!
Interesting most recent company filing with absolutely NO mention of nasal sprays….
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170721710
New investors, the CEO just surrendered his shares for tax planning purposes. Please join us in our misery and become a fellow bagholder!
BT BeaMed Technologies, LTD is a privately owned company. However, investors can purchase an equity share of BeaMed by investing in IPIX which is the minority owner of BeaMed. When you buy IPIX you have equity in both companies.
No one is buying it.
The CEO’s getting paid upward of $300/hr to do what exactly?
Any idea who’s banking $10000 to $15000 this week from IPIX?
Hopefully the CEO invested the balance of our capital.!
Nobody’s buying it!
No one is buying it and IPIX isn’t advancing it. B is dead.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170721710
IPIX is dead.
1.) the company doesn’t have financial resources to advance Brilacidin into clinical trials and 2.) the company plans to AVOID such investments of time and financial resources.
In the CEO’s own words from Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Research is still chugging along. Thank you for bringing info forward.
Maybe they think this is attractive from IPIX’s most recent 10Q -
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.”
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“
The CEO said yesterday the company is looking for additional investments with what little capital we have left and we believe him. B is dead.
Agree, nothing but dead spots under this pile of shit.
Grass is definitely not going to be growing under this investment.
The CEO clearly disposed millions of shares during the last hours of 2022 and couldn’t even enter his address correctly on the filing. This turd is toast.
LMAO. When wolves howl, sheep bleat in response.
Most recent filings show management’s plan is to spend capital on “investments” rather than clinical trials.
The CEO is banking on it.
I’ll be adding a boatload
2023 - No one is buying it.
Because no one knew in 2013 all Brilacidin could do
Among others. Isn’t that evident by the authors of the “independent” publishings?
Nope. Good guess though. He’s been poolside w/ the CEO in Boca.